Thrombophilic Risk of Factor V Leiden, Prothrombin G20210A, MTHFR, and Calreticulin Mutations in Essential Thrombocythemia Egyptian Patients

Table 4

Percentage of factor V Leiden, prothrombin gene, and MTHFR mutations in essential thrombocythemia patients with JAK2 V617F positive mutation versus the JAK2 V617F negative group.

		Jak2 V617F mutation
		Positive mutation		Negative mutation
		Count	%	Count	%
Factor V Leiden	Normal	39	59.1	27	40.9	0.3
	Heterozygous	39	72.2	15	27.8
Prothrombin gene mutation	Normal	60	64.5	33	35.5	0.9
	Heterozygous	18	66.7	9	33.3
MTHFR mutation	Normal	21	77.8	6	22.2	0.4
	Heterozygous	48	76.2	15	23.8
	Homozygous	9	30.0	21	70.0